SCHEMBL16184368

SCHEMBL16184368

CNc1nc(-c2cnccn2)nc2c(F)cc(-c3cc(F)cc(F)c3)cc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM5 P41594 1/20 0.38
▸ LATS1 O95835 1/20 0.35
▸ LATS2 Q9NRM7 1/20 0.35
▸ LRRK2 Q5S007 1/20 0.34
▸ CYP1A2 P05177 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ CLK4 Q9HAZ1 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ ALOX5AP P20292 2/20 0.32
▸ FEN1 P39748 2/20 0.32
▸ TGFBR1 P36897 2/20 0.32
▸ TGFBR2 P37173 2/20 0.32
▸ CDK8 P49336 1/20 0.32
▸ GSK3A P49840 1/20 0.32
▸ GSK3B P49841 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16184378 0.92 GRM5 (0.35) GRM5LATS1LATS2LRRK2CYP1A2
SCHEMBL16184364 0.92 LATS1 (0.37) GRM5LATS1LATS2LRRK2CYP1A2
SCHEMBL16184361 0.90 MAP4K4 (0.42) GRM5LATS1LATS2CYP1A2CYP3A4
SCHEMBL16184371 0.88 CYP17A1 (0.36) LATS1LATS2LRRK2CYP1A2CYP3A4
SCHEMBL14474187 0.88 SCN9A (0.38) GRM5LATS1LATS2CYP1A2CYP3A4
SCHEMBL16184369 0.86 NPC1 (0.44) LATS1LATS2LRRK2CYP1A2CYP3A4
SCHEMBL16185168 0.86 CHRNA7 (0.37) GRM5LATS1LATS2CYP2D6CYP2C9
SCHEMBL16184365 0.85 FEN1 (0.41) GRM5LATS1LATS2CYP1A2CYP3A4
SCHEMBL16184373 0.85 NPC1 (0.36) LATS1LATS2LRRK2CYP1A2CYP3A4
SCHEMBL16184367 0.85 NPC1 (0.39) LATS1LATS2CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB GRM5 37/4885LATS1 2182/4885LATS2 1457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback